Evidence map›Paper›PMID 21085048›Full record

ArticleThe Pediatric infectious disease journal2011

Fluconazole loading dose pharmacokinetics and safety in infants.

Lauren Piper, P Brian Smith, Christoph P Hornik, Ira M Cheifetz, Jeffrey S Barrett, Ganesh Moorthy, William W Hope, Kelly C Wade, Michael Cohen-Wolkowiez, Daniel K Benjamin

Abstract read
In one paragraph

Article in The Pediatric infectious disease journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 3 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 120 citations in OpenAlex.

  1. Pooled it
  2. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016
    Guideline
  3. Safety of fluconazole in paediatrics: a systematic review.European journal of clinical pharmacology · 2013
    Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Creativity in Pediatric Clinical Pharmacology: Study Design and Oral Dosage Forms.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2024
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Association between neonatal intensive care unit medication safety practices, adverse events, and death.Journal of perinatology : official journal of the California Perinatal Association · 2021
    Article
  16. Review of Fluconazole Treatment and Prophylaxis for Invasive Candidiasis in Neonates.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2021
    Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Lauren PiperDepartment of Pediatrics and Duke Clinical Research Institute, Duke University, Durham, NC, USA.
P Brian Smith
Christoph P Hornik
Ira M Cheifetz
Jeffrey S Barrett
Ganesh Moorthy
William W Hope
Kelly C Wade
Michael Cohen-Wolkowiez
Daniel K Benjamin
Clinical Research Institute · USChildren's Hospital of Philadelphia · USUniversity of Manchester · GB

Funding

Duke Research Training Program for PediatriciansT32HD043029 · NICHD · DUKE UNIVERSITY · PI BENJAMIN, DANIEL K. · 2002 to 2017
$3.7M
Prevention of Invasive Candidiasis: PK, Safety, and Neurodevelopmental OutcomesR01HD057956 · NICHD · DUKE UNIVERSITY · PI BENJAMIN, DANIEL K. · 2008 to 2012
$2.8M
Pediatric Pharmacology Research Unit NetworkU10HD037255 · NICHD · CHILDREN'S HOSP OF PHILADELPHIA · PI BARRETT, JEFFREY SCOTT · 2004 to 2009
$2.5M
North Carolina Collaborative PPRU NetworkU10HD045962 · NICHD · DUKE UNIVERSITY · PI BENJAMIN, DANIEL K. · 2004 to 2009
$2.1M
Prevention of Invasive Candidiasis: PK, Safety, and Neurodevelopmental OutcomesR01FD003519 · FDA · DUKE UNIVERSITY · PI BENJAMIN, DANIEL K. · 2008 to 2011
$1.6M
Mentorship of early-career pediatricians in quantitiative methods and therapeuticK24HD058735 · NICHD · DUKE UNIVERSITY · PI BENJAMIN, DANIEL K. · 2009 to 2018
$1.5M
Pharmacokinetics and Pharmacodynamics of Antibiotics in Premature InfantsK23HD064814 · NICHD · DUKE UNIVERSITY · PI COHEN-WOLKOWIEZ, MICHAEL · 2010 to 2013
$474k
PHARMACOKINETICS OF ANTIMICROBIAL AGENTS IN HIGH RISK INFANTSK23HD060040 · NICHD · DUKE UNIVERSITY · PI SMITH, PHILLIP BRIAN · 2009 to 2012
$445k
FDA HHS 1R01FD003519-01FDA HHS R01 FD003519NICHD NIH HHS 1K23HD060040-01NICHD NIH HHS 1K24HD058735-01NICHD NIH HHS 1R01HD057956-02NICHD NIH HHS 1U10-HD45962-05S1NICHD NIH HHS HHSN267200700051CNICHD NIH HHS K23 HD060040NICHD NIH HHS K23 HD064814NICHD NIH HHS K24 HD058735NICHD NIH HHS R01 HD057956NICHD NIH HHS T32 HD043029NICHD NIH HHS T32-HD043029-08NICHD NIH HHS U10 HD037255NICHD NIH HHS U10-HD037255NICHD NIH HHS U10 HD045962
6 · The paper itself

Abstract

backgroundInvasive candidiasis is a leading cause of morbidity and mortality in critically ill infants. Prompt administration of fluconazole and achievement of the therapeutic target (area under the curve 0 to 24 hours >400 mg*h/L) improve outcomes in candidemic patients. A loading dose of fluconazole is advised for older patients but has not been evaluated in infants. We sought to determine the pharmacokinetics and safety of a fluconazole loading dose in infants at risk for invasive fungal infection.

methodsWe enrolled 10 hospitalized infants <60 days old with suspected systemic fungal infection in this open-label study; 9 received a 25-mg/kg fluconazole loading dose followed by a maintenance dose of 12 mg/kg every 24 hours for 4 additional days. Plasma samples were obtained following the loading and steady-state doses (doses 3-5). We used a 1-compartment model to fit the data to estimate pharmacokinetic indices.

resultsData from 57 drug concentrations obtained from 8 infants (median postnatal age, 16 days [interquartile range, 13-32] and median gestational age, 37 weeks [35-38]) showed that the median fluconazole area under the curve 0 to 24 hours (mg*h/L) in this population was 479 (347-496). Of the 8 infants who received the loading dose, 5 (63%) achieved the therapeutic target on the first day of dosing, and all infants achieved a fluconazole 24-hour trough concentration >8 μg/mL. No adverse events were thought to be related to fluconazole therapy.

conclusionsA loading dose of fluconazole (25 mg/kg) was safe in this small cohort of young infants and achieved the therapeutic target more rapidly than traditional dosing.

Indexed as

Antifungal AgentsCandidiasisChromatography, LiquidFluconazoleHumansInfantInfant, NewbornPlasmaTandem Mass SpectrometryAntifungal AgentsFluconazole

Identifiers

PMID21085048
PMCPMC3078721
OpenAlexW2077952056

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.